drugset
drugset / Trial / NCT07513857

Trial of JYB1904 Injection in Adolescent Participants

NCT07513857 ↗

Phase 1 Not yet recruiting 12 enrolled Jemincare
NaSingle-groupOpen-labelTreatment

Summary

This Phase Ib Trial is Meant to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants With Allergic Diseases.

Timeline

Start
2026-05-17
Primary completion
2027-07-30
Completion
2027-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject OZUREPRUBART Monoclonal antibody 300 mg Subcutaneous

Indications

allergic disease